CLINICAL TRIALS PROFILE FOR MEBENDAZOLE
✉ Email this page to a colleague
All Clinical Trials for Mebendazole
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00116493 ↗ | Severe Anemia Treatment Trials, Pakistan | Completed | Aga Khan University | Phase 3 | 2004-04-01 | The purpose of this study is to test the efficacy of two enhanced regimens (deworming and multivitamins) in the treatment of severe anemia in pregnant women and children 6-24 months of age in Karachi, Pakistan. |
| NCT00116493 ↗ | Severe Anemia Treatment Trials, Pakistan | Completed | Johns Hopkins Bloomberg School of Public Health | Phase 3 | 2004-04-01 | The purpose of this study is to test the efficacy of two enhanced regimens (deworming and multivitamins) in the treatment of severe anemia in pregnant women and children 6-24 months of age in Karachi, Pakistan. |
| NCT01050452 ↗ | Safety and Efficacy of Drug Combinations Against Trichuris Trichiura | Completed | DBL -Institute for Health Research and Development | N/A | 2007-10-01 | This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of albendazole (ALB), mebendazole (MBD) and ivermectin (IVM) separately, and ALB and MBD each in combination with IVM in the treatment of Trichuris trichiura in children aged 5-14 years. |
| NCT01173562 ↗ | A Safety Study of Mebendazole in Children 2 to 10 Years of Age | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2010-02-01 | The purpose of this study is to assess the safety and tolerability of mebendazole 500-mg chewable tablet formulation in a pediatric population. Mebendazole is a drug used for the treatment of soil-transmitted parasitic helminth (STH) (ie, parasitic worm) infections such as pinworm, whipworm, common roundworm, common hookworm, and American hookworm. |
| NCT01314937 ↗ | The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas | Completed | Asociacion Civil Selva Amazonica | Phase 4 | 2011-09-01 | Worldwide, over 2 billion people suffer from worm infections in developing countries. These infections are especially damaging to the health of children, resulting in both short-term and lifelong disability. Older children with worm infections are more likely to be stunted, underweight, vulnerable to other illnesses and perform poorly in school compared to non-infected children. Large-scale deworming programs in school-age children are therefore recommended by the World Health Organization (WHO). WHO also recommends deworming of preschool-age children (as of 12 months of age) in these areas; however, the benefits of deworming, especially in the 12-24 month age group, have been inadequately studied. This knowledge is urgently needed as studies show that all children have a similar potential for healthy growth and development, provided that appropriate nutrition and health interventions are given in the critical window of opportunity before the age of two. Therefore, the investigators are proposing to undertake a randomized controlled trial to determine the effect of deworming program for improving growth and development in children between 12 and 24 months of age. Our results will provide solid rigorous evidence on if, when, and how often, deworming should be integrated into routine child health care packages provided by Ministries of Health in the 130 countries in the world where worm infections are endemic. |
| NCT01314937 ↗ | The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas | Completed | Canadian Institutes of Health Research (CIHR) | Phase 4 | 2011-09-01 | Worldwide, over 2 billion people suffer from worm infections in developing countries. These infections are especially damaging to the health of children, resulting in both short-term and lifelong disability. Older children with worm infections are more likely to be stunted, underweight, vulnerable to other illnesses and perform poorly in school compared to non-infected children. Large-scale deworming programs in school-age children are therefore recommended by the World Health Organization (WHO). WHO also recommends deworming of preschool-age children (as of 12 months of age) in these areas; however, the benefits of deworming, especially in the 12-24 month age group, have been inadequately studied. This knowledge is urgently needed as studies show that all children have a similar potential for healthy growth and development, provided that appropriate nutrition and health interventions are given in the critical window of opportunity before the age of two. Therefore, the investigators are proposing to undertake a randomized controlled trial to determine the effect of deworming program for improving growth and development in children between 12 and 24 months of age. Our results will provide solid rigorous evidence on if, when, and how often, deworming should be integrated into routine child health care packages provided by Ministries of Health in the 130 countries in the world where worm infections are endemic. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Mebendazole
Condition Name
Clinical Trial Locations for Mebendazole
Trials by Country
Clinical Trial Progress for Mebendazole
Clinical Trial Phase
Clinical Trial Sponsors for Mebendazole
Sponsor Name
